MedTrace Logo

A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis

NCT03789292 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 648

Last updated 2021-11-17

Study results available
· View outcomes & findings →

Summary

This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis

Conditions

Interventions

BIOLOGICAL

CT-P17 SC

Subcutaneous injection of Adalimumab 40mg every two weeks

BIOLOGICAL

Humira SC

Subcutaneous injection of Adalimumab 40mg every two weeks

Sponsors & Collaborators

Principal Investigators

  • MinJi Ma · Celltrion, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-26
Primary Completion
2019-10-08
Completion
2020-04-24

Countries

  • Bulgaria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03789292 on ClinicalTrials.gov